Clinical-alimentary tract5-aminosalicylic acids and the risk of renal disease: A large British epidemiologic study☆
Section snippets
Data source
In the United Kingdom, health care delivery is centered on general practitioners (GPs) whose responsibilities include primary health care and specialist referrals. The information for this study was obtained from the General Practice Research Database (GPRD), which contains the computerized medical records of general practices across the United Kingdom.24 Approximately 6% of the total registered population of England and Wales is represented in the database, and it includes a cumulative total
Results
A total of 37,984 patients in the GPRD population had a record of IBD or a prescription for 5-ASA; 19,025 were assigned to the 5-ASA/IBD cohort. The mean age of these patients was 48 years, and 53.0% were women. They were followed for an average of 6 years. Their mean number of 5-ASA prescriptions during follow-up was 19.4 (median 10): The mean duration of each prescription was 1 month. The distribution of the type of prescribed 5-ASA in the 5-ASA/IBD cohort was as follows in these patients:
Discussion
This study found that IBD patients who were 5-ASA users had an increased risk of renal disease. However, after adjustment, the risks of 5-ASA users were comparable with controls. In only a few records was renal disease attributed to interstitial nephritis or 5-ASA use. These findings indicate that the incidence of 5-ASA-induced renal disease is rare.
We also found that both IBD patients not using 5-ASA drugs and past 5-ASA users had increased risks of renal disease. Risk of renal disease was
References (43)
- et al.
Acute renal failure in a 53-year-old woman with Crohn’s disease treated with 5-aminosalicylic acid
Am J Kidney Dis
(2001) - et al.
The UK General Practice Research Database
Lancet
(1997) - et al.
Inflammatory bowel disease and the risk of fracture
Gastroenterology
(2003) - et al.
Primary chronic interstitial nephritis in Crohn’s disease
Gastroenterology
(2002) - et al.
Sulphasalazine induced renal failure
Gut
(1992) - et al.
Nephrotic syndrome associated with sulfasalazine
Br Med J
(1990) Sulphasalazine and nephrotic syndrome
Am J Gastroenterol
(1993)- et al.
Mesalazine associated nephrogenic diabetes insipidus presenting as weight loss
Gut
(1992) Acute interstitial nephritis due to 5-aminosalicylic acid
Can Med Assoc J
(1990)- et al.
Mesalazine induced interstitial nephritis
Gut
(1994)
Mesalazine-associated tubulo-interstitial nephritis in inflammatory bowel disease
Clin Nephrol
Late onset interstitial nephritis
Br Med J
Interstitial nephritis in patients with inflammatory bowel disease treated with mesalamine
Clin Gastroenterol
Early renal failure after mesalazine (case report)
Acta Univ Palacki Olumuc Fac Med
Acute interstitial nephritis due to 5-aminosalicylic acid
Internist
Nephritis due to 5-aminosalicylic acid
Deutsche Med Wschr
Side effects of medicinestubulointerstitial nephritis by mesalazine (5-ASA) drugs
Ned Tijdschr Geneesk
Chronic interstitial nephritis after treatment with 5-aminosalicylic acid
Deutsche Med Wschr
Nephrotic syndrome after treatment with 5-aminosalicylic acid
Br Med J
Mesalazine-induced interstitial nephritis
Neprol Dial Transplant
Nephrotic syndrome from 5-ASA for ulcerative colitis
J Clin Gastroenterol
Cited by (136)
Cobalt aluminum layered double hydroxide as a superior electrochemical probe for the sensitive detection of anti-inflammatory agent mesalazine
2024, Journal of Alloys and CompoundsInflammatory Bowel Disease With Chronic Kidney Disease and Acute Kidney Injury
2023, American Journal of Preventive MedicineGlomerulonephritis and inflammatory bowel disease: A tale of gut-kidney axis dysfunction
2023, Autoimmunity ReviewsCrohn's Disease of the Elderly: Unique Biology and Therapeutic Efficacy and Safety
2022, Gastroenterology Clinics of North AmericaKidney function monitoring to prevent 5-aminosalicylic acid nephrotoxicity: What the gastroenterologist should know
2021, Digestive and Liver DiseaseCitation Excerpt :In the first one, 59 news cases of nephrotoxicity were identified by the British Society of Gastroenterology (BSG) during a two-years prospective study [32]. In the second study, 130 out of 19,025 IBD patients using 5-ASA developed renal disease from the United Kingdom General Practice Research Database [16]. In addition, the prevalence of deterioration of kidney function after 5-ASA treatment is of 0.06% according to the safety data from 18 clinical trials assessing the efficacy of 5-ASA in 1638 IBD patients [33]; this prevalence rate is low, but the follow-up was only of 6 to 12 months, thus underestimating it.
Inflammatory Bowel Diseases Are Associated With an Increased Risk for Chronic Kidney Disease, Which Decreases With Age
2020, Clinical Gastroenterology and Hepatology
- ☆
Supported by Procter & Gamble Pharmaceuticals.